Callisto and Tauns Enter Capital and Business Alliance for Medical AI Infrastructure
The alliance merges a medical AI data platform with a diagnostics manufacturer's customer network and regulatory infrastructure to create a large-scale multimodal medical data platform for drug discovery AI.
Reporting from 1 source: ASCII.jp.
Callisto and TAUNS Laboratories have agreed to a capital and business alliance to build a medical data infrastructure and AI utilization platform. The partnership will combine Callisto's medical image data platform and AI expertise with Tauns' medical institution network, commercialization infrastructure, and diagnostics knowledge. The goal is to accelerate expansion into the pharmaceutical field and overseas markets.
The two companies plan to cross-utilize medical images, clinical information, molecular data, and biobank specimens. Callisto, which operates a medical image data platform for AI development and clinical research, has collaborated with domestic medical institutions to build datasets and conducted contract work for drug discovery and medical AI. Tauns, an in vitro diagnostic drug manufacturer, brings a network of medical institutions, specimen testing expertise, and commercialization infrastructure including pharmaceutical affairs and distribution. By combining these resources, the partners aim to develop a large-scale multimodal medical data infrastructure and AI utilization platform. They also intend to accelerate expansion into the pharmaceutical field and overseas markets.
Synthesized by Yomimono from the 1 cited source below, including Japanese-language reporting where cited, then editorially reviewed before publishing.